Bristol Already Preparing Daclatasvir Supplemental Filings In HCV
This article was originally published in The Pink Sheet Daily
Executive Summary
The pharma unveils impressive Phase III cure rates in combination study of its NS5A inhibitor with sofosbuvir in hepatitis C patients co-infected with HIV. It plans to file sNDAs for that and other difficult-to-treat subpopulations if the agent obtains FDA approval after reply to “complete response” letter.